[SCHEDULE 13D/A] Guardian Pharmacy Services, Inc. SEC Filing

Rhea-AI Filing Summary

Gilead Sciences (GILD) – Form 4 insider transaction: Chairman & CEO Daniel P. O’Day sold a total of 10,000 common shares on 28 Jul 2025 under a Rule 10b5-1 trading plan adopted 28 Feb 2025.

• Sales executed in two blocks: 1,655 sh @ $113.17 avg and 8,345 sh @ $114.09 avg, implying total proceeds of roughly $1.13 million.
• Post-sale direct ownership falls to 605,725 shares, down ~1.6 % from 615,725 pre-trade.
• No derivative transactions were reported.

The modest size and pre-planned nature of the sale suggest limited informational value, but investors often monitor CEO transactions for sentiment cues.

Positive

• CEO retains 605,725 shares, maintaining strong equity alignment with shareholders.

Negative

• Insider selling by the CEO (10,000 shares) can be perceived as a mild negative sentiment signal, even if pre-planned.

Insights

Securities Analyst

TL;DR: Small, pre-planned CEO sale; neutral signal.

O’Day’s 10k-share sale represents <2 % of his stake and was executed under a 10b5-1 plan, limiting discretionary timing. With >600k shares still held, alignment with shareholders remains high. The dollar amount is immaterial to GILD’s $140 bn market cap, so trading liquidity and valuation impact are negligible. I view this filing as routine and do not change my model or rating.

Corporate Governance Expert

TL;DR: Governance-compliant sale; watch pattern, not event.

The filing reflects good governance: advance 10b5-1 adoption and transparent price ranges. Frequency and aggregate volume of future sales will matter more than this isolated transaction. No red flags on ownership commitment; O’Day retains substantial skin in the game.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Guardian Pharmacy Services, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

40145W101

(CUSIP Number)

Bindley Capital Partners I LLC
(Attn: William E. Bindley), 8909 Purdue Road, Suite 500
Indianapolis, IN, 46268
(317) 704-4162

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/29/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

Bindley Capital Partners I, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

INDIANA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 8,039,993.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 8,039,993.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

8,039,993.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

22.2 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Bindley Capital Partners I, LLC ("Bindley Capital") currently owns an aggregate of 1,939,817 shares of Class A common stock, par value $0.001 per share ("Class A common stock") and 18,300,526 shares of Class B common stock, par value $0.001 per share ("Class B common stock"), of Guardian Pharmacy Services, Inc. (the "Issuer"). Pursuant to the Issuer's Amended and Restated Certificate of Incorporation (the "Charter"), such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Bindley Capital, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2025 (the "10-Q")), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

William E. Bindley

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 8,039,993.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 8,039,993.00

11

Aggregate amount beneficially owned by each reporting person

8,039,993.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

22.2 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

William E. Bindley shares voting and investment power with Thomas J. Salentine, Jr. over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 8, 10 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Bindley, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

Thomas J. Salentine, Jr.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO, PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 35,714.00
8	Shared Voting Power 8,039,993.00
9	Sole Dispositive Power 35,714.00
10	Shared Dispositive Power 8,039,993.00

11

Aggregate amount beneficially owned by each reporting person

8,075,707.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

22.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Thomas J. Salentine, Jr. directly owns 35,714 shares of Class A common stock. Mr. Salentine, Jr. also shares voting and investment power with William E. Bindley over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7 and 9 in the table above represent 35,714 outstanding shares of Class A common stock directly owned by Mr. Salentine, Jr. The shares reported in Rows 8 and 10 represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Salentine, Jr., and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The shares reported in Row 11 represent the aggregate amount of shares of Class A common stock beneficially owned by the Reporting Person. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

Pharmacy Investors, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

INDIANA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,863,564.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,863,564.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,863,564.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Pharmacy Investors, LLC ("Pharmacy Investors") currently owns an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Pharmacy Investors, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

John Ackerman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,863,564.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,863,564.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,863,564.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

John Ackerman has voting and investment power over an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock currently owned by Pharmacy Investors by virtue of his position as Manager of Pharmacy Investors, LLC. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Mr. Ackerman, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

Cardinal Equity Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 620,851.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 620,851.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

620,851.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Cardinal Equity Fund, L.P. ("Cardinal") currently owns an aggregate of 149,794 shares of Class A common stock and 1,413,171 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 149,794 outstanding shares of Class A common stock beneficially owned by Cardinal, and 471,057 shares of Class A common stock that will be issued to Cardinal on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. Investment and voting decisions for the shares held by Cardinal require unanimous consent of the investment committee of Cardinal Equity Partners, LLC, the general partner of Cardinal. The investment committee consists of John Ackerman, James L. Smeltzer, Peter J. Munson, Darrell E. Zink and Michael E. Smith. Therefore, no individual member of the investment committee is deemed to be the beneficial owner of the shares reported in this Schedule 13D. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

Fred P. Burke

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,711,845.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,711,845.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,711,845.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Fred P. Burke currently owns an aggregate of 413,019 shares of Class A common stock and 3,896,477 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 413,019 outstanding shares of Class A common stock beneficially owned by Mr. Burke, and 1,298,826 shares of Class A common stock that will be issued to Mr. Burke on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

David K. Morris

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 845,979.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 845,979.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

845,979.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

David K. Morris currently owns an aggregate of 204,110 shares of Class A common stock and 1,925,608 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 204,110 outstanding shares of Class A common stock beneficially owned by Mr. Morris, and 641,869 shares of Class A common stock that will be issued to Mr. Morris on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

CUSIP No. 40145W101

1

Name of reporting person

G. Kendall Forbes

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 802,091.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 802,091.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

802,091.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.2 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

G. Kendall Forbes currently owns an aggregate of 193,521 shares of Class A common stock and 1,825,710 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 193,521 outstanding shares of Class A common stock beneficially owned by Mr. Forbes, and 608,570 shares of Class A common stock that will be issued to Mr. Forbes on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, par value $0.001 per share
(b)	Name of Issuer: Guardian Pharmacy Services, Inc.
(c)	Address of Issuer's Principal Executive Offices: 300 Galleria Parkway SE, Suite 800, Atlanta, GEORGIA , 30339.
Item 1 Comment: EXPLANATORY NOTE: This Schedule 13D is intended to serve as Amendment No. 2 to the Statement on Schedule 13D ("Amendment No. 2") related to the shares of Class A common stock, par value $0.001 per share ("Class A common stock") of Guardian Pharmacy Services, Inc. (the "Issuer"), and amends the initial statement on Schedule 13D filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, and as further amended by this Amendment No. 2 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 2 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 2 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons").
Item 3.	Source and Amount of Funds or Other Consideration
	As of the date hereof, the Reporting Persons, collectively, beneficially own 13,920,037 shares of Class A common stock.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, the Reporting Persons, collectively, beneficially own 13,920,037 shares of Class A common stock, representing approximately 38.4% of the shares of Class A common stock, calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q, and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
(b)	The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.
(c)	Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D.
(d)	Except as described herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A common stock of the Issuer beneficially owned by the Reporting Persons as described in this Item 5.
(e)	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Stockholders' Agreement, dated as of September 25, 2024, by and among Guardian Pharmacy Services, Inc., Bindley Capital Partners I, LLC, Pharmacy Investors, LLC, Cardinal Equity Fund LP, Fred Burke, David Morris and Kendall Forbes (incorporated by reference to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2024). Exhibit 99.2 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated by reference to the Schedule 13D filed with the Securities and Exchange Commission on February 3, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bindley Capital Partners I, LLC

Signature:	/s/ Thomas J. Salentine, Jr.
Name/Title:	Member
Date:	07/29/2025

William E. Bindley

Signature:	/s/ William E. Bindley, individually
Name/Title:	William E. Bindley, individually
Date:	07/29/2025

Thomas J. Salentine, Jr.

Signature:	/s/ Thomas J. Salentine, Jr., individually
Name/Title:	Thomas J. Salentine, Jr., individually
Date:	07/29/2025

Pharmacy Investors, LLC

Signature:	/s/ John Ackerman
Name/Title:	Managing Member
Date:	07/29/2025

John Ackerman

Signature:	/s/ John Ackerman, individually
Name/Title:	John Ackerman, individually
Date:	07/29/2025

Cardinal Equity Fund, L.P.

Signature:	/s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner
Name/Title:	Managing Member
Date:	07/29/2025

Fred P. Burke

Signature:	/s/ Fred P. Burke, individually
Name/Title:	Fred P. Burke, individually
Date:	07/29/2025

David K. Morris

Signature:	/s/ David K. Morris, individually
Name/Title:	David K. Morris, individually
Date:	07/29/2025

G. Kendall Forbes

Signature:	/s/ G. Kendall Forbes, individually
Name/Title:	G. Kendall Forbes, individually
Date:	07/29/2025

FAQ

How many GILD shares did CEO Daniel O’Day sell?

He sold 10,000 common shares on 28 Jul 2025.

What were the sale prices for the GILD insider transaction?

Average prices were $113.17 for 1,655 shares and $114.09 for 8,345 shares.

Was the sale executed under a 10b5-1 plan?

Yes, the trades were made pursuant to a Rule 10b5-1 plan adopted on 28 Feb 2025.

How many Gilead shares does the CEO now own?

After the sale, Daniel O’Day directly owns 605,725 shares of GILD.

Does this filing indicate a major change in insider ownership?

No, the sale reduced holdings by ~1.6 %, a relatively small change.